$BYSI
BeyondSpring Inc. Stock $bysi

$bysi Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 20-F Financial Statement

#000117184323002373 Filed on April 18, 2023

Income Statement

Concept	2022 Q4	2022	2021 Q4
Revenue	$1.351M	$1.351M	$338.0K
YoY Change	299.7%	0.0%	87.78%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$13.01M	$13.01M	$5.044M
YoY Change	157.89%	-57.63%	-51.36%
% of Gross Profit
Research & Development	$25.58M	$25.58M	$5.786M
YoY Change	342.14%	-30.65%	-31.28%
% of Gross Profit
Depreciation & Amortization	$232.0K	$232.0K	$7.000K
YoY Change	3214.29%	280.33%	-76.67%
% of Gross Profit
Operating Expenses	$38.59M	$38.59M	$10.83M
YoY Change	256.33%	-42.91%	-42.39%
Operating Profit		-$37.24M
YoY Change		-43.78%
Interest Expense	-$251.0K	$17.00K	$138.0K
YoY Change	-281.88%	-92.98%	-42.5%
% of Operating Profit
Other Income/Expense, Net	$1.373M	$1.122M	$608.0K
YoY Change	125.82%	54.76%
Pretax Income	-$36.12M	-$36.12M	-$9.746M
YoY Change	270.58%	-44.12%	-46.97%
Income Tax	$163.0K	$163.0K	$982.0K
% Of Pretax Income
Net Earnings	-$33.28M	-$33.28M	-$9.513M
YoY Change	249.83%	-48.15%	-45.95%
Net Earnings / Revenue	-2463.29%	-2463.29%	-2814.5%
Basic Earnings Per Share		-$0.85
Diluted Earnings Per Share	-$0.85	-$0.85	-$243.6K
COMMON SHARES
Basic Shares Outstanding	39.00M	39.09M
Diluted Shares Outstanding

Balance Sheet

Concept	2022 Q4	2022	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$37.27M	$37.27M	$72.37M
YoY Change	-48.5%	-48.5%	-33.91%
Cash & Equivalents	$34.40M	$34.40M	$41.63M
Short-Term Investments	$2.872M	$2.872M	$30.74M
Other Short-Term Assets	$1.255M	$1.255M	$2.755M
YoY Change	-54.45%	-54.45%	588.75%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$38.52M	$38.52M	$75.12M
YoY Change	-48.72%	-48.72%	-33.75%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.868M	$7.352M	$3.406M
YoY Change	-45.16%	115.85%	41.92%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$347.0K	$347.0K	$3.119M
YoY Change	-88.87%	-88.87%	139.92%
Total Long-Term Assets	$7.699M	$7.699M	$6.525M
YoY Change	17.99%	17.99%	81.25%
TOTAL ASSETS
Total Short-Term Assets	$38.52M	$38.52M	$75.12M
Total Long-Term Assets	$7.699M	$7.699M	$6.525M
Total Assets	$46.22M	$46.22M	$81.65M
YoY Change	-43.39%	-43.39%	-30.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.081M	$1.081M	$1.656M
YoY Change	-34.72%	-34.72%	-24.73%
Accrued Expenses	$2.470M	$4.782M	$6.625M
YoY Change	-62.72%	-27.82%	-30.26%
Deferred Revenue	$1.351M		$1.369M
YoY Change	-1.31%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$1.569M
YoY Change	-100.0%	-100.0%
Total Short-Term Liabilities	$7.352M	$7.352M	$15.16M
YoY Change	-51.49%	-51.49%	9.82%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$3.661M	$41.88M	$40.12M
YoY Change	-90.87%	4.39%	2765.43%
Total Long-Term Liabilities	$41.88M	$41.88M	$40.12M
YoY Change	4.39%	4.39%	1014.33%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.352M	$7.352M	$15.16M
Total Long-Term Liabilities	$41.88M	$41.88M	$40.12M
Total Liabilities	$49.23M	$52.20M	$54.96M
YoY Change	-10.43%	-5.03%	91.51%
SHAREHOLDERS EQUITY
Retained Earnings	-$375.3M		-$342.0M
YoY Change	9.73%
Common Stock	$4.000K		$4.000K
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$5.979M	-$5.979M	$26.68M
YoY Change
Total Liabilities & Shareholders Equity	$46.22M	$46.22M	$81.65M
YoY Change	-43.39%	-43.39%	-30.22%

Cashflow Statement

Concept	2022 Q4	2022	2021 Q4
OPERATING ACTIVITIES
Net Income	-$33.28M	-$33.28M	-$9.513M
YoY Change	249.83%	-48.15%	-45.95%
Depreciation, Depletion And Amortization	$232.0K	$232.0K	$7.000K
YoY Change	3214.29%	280.33%	-76.67%
Cash From Operating Activities	-$28.15M	-$27.46M	-$16.92M
YoY Change	66.4%	-41.87%	142.73%
INVESTING ACTIVITIES
Capital Expenditures	$34.00K	$34.00K	-$2.805M
YoY Change	-101.21%	-101.2%	13925.0%
Acquisitions
YoY Change
Other Investing Activities	$18.28M	$18.28M	-$1.924M
YoY Change	-1050.16%	-204.05%
Cash From Investing Activities	$18.25M	$17.56M	-$4.729M
YoY Change	-485.85%	-186.02%	23545.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.431M	$3.431M	0.000
YoY Change		343000.0%	-100.0%
NET CHANGE
Cash From Operating Activities	-28.15M	-$27.46M	-16.92M
Cash From Investing Activities	18.25M	$17.56M	-4.729M
Cash From Financing Activities	3.431M	$3.431M	0.000
Net Change In Cash	-6.473M	-$7.229M	-21.65M
YoY Change	-70.1%	-89.31%	-127.44%
FREE CASH FLOW
Cash From Operating Activities	-$28.15M	-$27.46M	-$16.92M
Capital Expenditures	$34.00K	$34.00K	-$2.805M
Free Cash Flow	-$28.19M	-$27.50M	-$14.11M
YoY Change	99.71%	-38.06%	103.06%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	369200000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	368857000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-341997000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-375276000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-523000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	436000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	26684000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-5979000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001677940
CY2022	dei	Entity Registrant Name EntityRegistrantName	BeyondSpring Inc.
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38927563
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38927563
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38999597
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38999597
CY2022Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2022	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2020	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2021	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	pure
CY2020	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2021Q4	bysi	Restricted Net Assets RestrictedNetAssets	0	usd
CY2022Q4	bysi	Restricted Net Assets RestrictedNetAssets	0	usd
CY2019	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	usd
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	pure
CY2022	dei	Document Type DocumentType	20-F
CY2022	dei	Document Registration Statement DocumentRegistrationStatement	false
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Document Shell Company Report DocumentShellCompanyReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-38024
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	E9
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	28 Liberty Street, 39th Floor
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10005
CY2022	dei	Security12b Title Security12bTitle	Ordinary Shares, par value $0.0001 per share
CY2022	dei	Trading Symbol TradingSymbol	BYSI
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	38999597
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Document Accounting Standard DocumentAccountingStandard	U.S. GAAP
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022	dei	Auditor Firm AuditorFirmId	1408
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2022	dei	Auditor Name AuditorName	Ernst & Young Hua Ming LLP
CY2022	dei	Auditor Location AuditorLocation	Beijing, the People’s Republic of China
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41625000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34396000	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	30743000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	2872000	usd
CY2021Q4	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	1735000	usd
CY2022Q4	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	492000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1020000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	763000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	75123000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	38523000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1422000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1868000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1984000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5484000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3119000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	347000	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	6525000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	7699000	usd
CY2021Q4	us-gaap	Assets Assets	81648000	usd
CY2022Q4	us-gaap	Assets Assets	46222000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1656000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1081000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3858000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2470000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	538000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	966000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1369000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1351000	usd
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1569000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	6165000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1484000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15155000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7352000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1468000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3995000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	37939000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	34221000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	709000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3661000	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	40116000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	41877000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	55271000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	49229000	usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	5454000	usd
CY2022Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	11074000	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	-5761000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-8102000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	20923000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-14081000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	81648000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	46222000	usd
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	180000	usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1351000	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1351000	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	41793000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	36888000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25582000	usd
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	22598000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	30703000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13008000	usd
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-64211000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-66240000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-37239000	usd
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	355000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	231000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-429000	usd
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	116000	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	98000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	195000	usd
CY2020	us-gaap	Interest Expense InterestExpense	85000	usd
CY2021	us-gaap	Interest Expense InterestExpense	87000	usd
CY2022	us-gaap	Interest Expense InterestExpense	17000	usd
CY2020	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	4000	usd
CY2021	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	1360000	usd
CY2022	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	1373000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-63821000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-64638000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-36117000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3570000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	163000	usd
CY2020	us-gaap	Profit Loss ProfitLoss	-63821000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-68208000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-36280000	usd
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-2848000	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-4029000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-3001000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-60973000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-64179000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-33279000	usd
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.03
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.64
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.85
CY2020	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	29984284
CY2021	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	39023643
CY2022	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	39093246
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-530000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-296000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1483000	usd
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	5000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-5000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-64351000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-68499000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-34802000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-2941000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-4094000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-2482000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-61410000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-64405000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-32320000	usd
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	31131000	usd
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	111594000	usd
CY2020	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	80000	usd
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	8171000	usd
CY2020	bysi	Capital Contribution To A Subsidiary Effect On Stockholders Equity CapitalContributionToASubsidiaryEffectOnStockholdersEquity	0	usd
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-530000	usd
CY2020	us-gaap	Profit Loss ProfitLoss	-63821000	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	86625000	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	3282000	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited	310000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	83000	usd
CY2021	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	258000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-291000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-68208000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	20923000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	1662000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited	7000	usd
CY2022	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	1857000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1478000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-36280000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-14081000	usd
CY2020	us-gaap	Profit Loss ProfitLoss	-63821000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-68208000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-36280000	usd
CY2020	us-gaap	Depreciation Depreciation	77000	usd
CY2021	us-gaap	Depreciation Depreciation	61000	usd
CY2022	us-gaap	Depreciation Depreciation	232000	usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	8194000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	3152000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1666000	usd
CY2020	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	659000	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	546000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	912000	usd
CY2020	bysi	Gain Loss On Derecognition Of Right Of Use Assets GainLossOnDerecognitionOfRightOfUseAssets	-0	usd
CY2021	bysi	Gain Loss On Derecognition Of Right Of Use Assets GainLossOnDerecognitionOfRightOfUseAssets	-22000	usd
CY2022	bysi	Gain Loss On Derecognition Of Right Of Use Assets GainLossOnDerecognitionOfRightOfUseAssets	-0	usd
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	635000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0	usd
CY2020	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-0	usd
CY2021	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	144000	usd
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	19000	usd
CY2020	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-0	usd
CY2021	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	444000	usd
CY2022	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	1071000	usd
CY2020	bysi	Increase Decrease In Shortterm Investments IncreaseDecreaseInShorttermInvestments	-0	usd
CY2021	bysi	Increase Decrease In Shortterm Investments IncreaseDecreaseInShorttermInvestments	13025000	usd
CY2022	bysi	Increase Decrease In Shortterm Investments IncreaseDecreaseInShorttermInvestments	-10172000	usd
CY2020	bysi	Increase Decrease In Advances To Suppliers IncreaseDecreaseInAdvancesToSuppliers	-1014000	usd
CY2021	bysi	Increase Decrease In Advances To Suppliers IncreaseDecreaseInAdvancesToSuppliers	-1770000	usd
CY2022	bysi	Increase Decrease In Advances To Suppliers IncreaseDecreaseInAdvancesToSuppliers	-1243000	usd
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-52000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	496000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-91000	usd
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	334000	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	294000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-1411000	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-321000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-560000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-575000	usd
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-291000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1711000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1388000	usd
CY2020	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-621000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-518000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1455000	usd
CY2020	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	2372000	usd
CY2021	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	2535000	usd
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-4669000	usd
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	9275000	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	30033000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1351000	usd
CY2020	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	674000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	2930000	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-43745000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-47242000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27464000	usd
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	52000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2844000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	34000	usd
CY2020	bysi	Proceeds From The Return Of Property And Equipment Investing Activities ProceedsFromTheReturnOfPropertyAndEquipmentInvestingActivities	0	usd
CY2021	bysi	Proceeds From The Return Of Property And Equipment Investing Activities ProceedsFromTheReturnOfPropertyAndEquipmentInvestingActivities	0	usd
CY2022	bysi	Proceeds From The Return Of Property And Equipment Investing Activities ProceedsFromTheReturnOfPropertyAndEquipmentInvestingActivities	717000	usd
CY2020	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	-0	usd
CY2021	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	44232000	usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	32197000	usd
CY2020	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	0	usd
CY2021	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	1663000	usd
CY2022	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	0	usd
CY2020	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	0	usd
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	25000000	usd
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	49761000	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-52000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-20413000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	17560000	usd
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	112577000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2020	bysi	Proceeds From Issuance Of Redeemable Noncontrolling Interests ProceedsFromIssuanceOfRedeemableNoncontrollingInterests	5233000	usd
CY2021	bysi	Proceeds From Issuance Of Redeemable Noncontrolling Interests ProceedsFromIssuanceOfRedeemableNoncontrollingInterests	0	usd
CY2022	bysi	Proceeds From Issuance Of Redeemable Noncontrolling Interests ProceedsFromIssuanceOfRedeemableNoncontrollingInterests	5000000	usd
CY2020	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	80000	usd
CY2021	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	usd
CY2022	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	usd
CY2020	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	278000	usd
CY2021	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	0	usd
CY2022	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	0	usd
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	83000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	939000	usd
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	44000	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	-0	usd
CY2020	bysi	Payments Of Issuance Of Redeemable Noncontrolling Interests PaymentsOfIssuanceOfRedeemableNoncontrollingInterests	-0	usd
CY2021	bysi	Payments Of Issuance Of Redeemable Noncontrolling Interests PaymentsOfIssuanceOfRedeemableNoncontrollingInterests	38000	usd
CY2022	bysi	Payments Of Issuance Of Redeemable Noncontrolling Interests PaymentsOfIssuanceOfRedeemableNoncontrollingInterests	-0	usd
CY2020	us-gaap	Proceeds From Issuance Of Unsecured Debt ProceedsFromIssuanceOfUnsecuredDebt	635000	usd
CY2021	us-gaap	Proceeds From Issuance Of Unsecured Debt ProceedsFromIssuanceOfUnsecuredDebt	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Unsecured Debt ProceedsFromIssuanceOfUnsecuredDebt	0	usd
CY2020	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	35000	usd
CY2021	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	usd
CY2020	us-gaap	Repayments Of Unsecured Debt RepaymentsOfUnsecuredDebt	-0	usd
CY2021	us-gaap	Repayments Of Unsecured Debt RepaymentsOfUnsecuredDebt	-0	usd
CY2022	us-gaap	Repayments Of Unsecured Debt RepaymentsOfUnsecuredDebt	1569000	usd
CY2020	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	64000	usd
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	-0	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	-0	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	117835000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3431000	usd
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-434000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-258000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-756000	usd
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	73604000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-67912000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7229000	usd
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	35933000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	109537000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	41625000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	109537000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	41625000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	34396000	usd
CY2020	us-gaap	Interest Paid Net InterestPaidNet	85000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	91000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	17000	usd
CY2020	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	166000	usd
CY2021	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	98000	usd
CY2022	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	136000	usd
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	295000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1181000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4411000	usd
CY2020	bysi	Rightofuse Asset Obtained Released In Exchange For Operating Lease Liability RightofuseAssetObtainedReleasedInExchangeForOperatingLeaseLiability	0	usd
CY2021	bysi	Rightofuse Asset Obtained Released In Exchange For Operating Lease Liability RightofuseAssetObtainedReleasedInExchangeForOperatingLeaseLiability	-803000	usd
CY2022	bysi	Rightofuse Asset Obtained Released In Exchange For Operating Lease Liability RightofuseAssetObtainedReleasedInExchangeForOperatingLeaseLiability	0	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">1.</em></b></p> </td><td style="width: auto;"> <p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Nature of the business</b></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 18pt;">BeyondSpring Inc. (the “Company”) was incorporated in the Cayman Islands on <em style="font: inherit;"> November 21, 2014. </em>The Company and its subsidiaries (collectively, the “Group”) are principally engaged in clinical stage biopharmaceutical activities focused on the development of innovative cancer therapies. The Company is under the control of Mr. Linqing Jia and Dr. Lan Huang as a couple (collectively, the “Founders”) since its incorporation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">On <em style="font: inherit;"> March 14, 2017, </em>the Company completed its initial public offering (“IPO”) on the NASDAQ Capital Market.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">On <em style="font: inherit;"> May 21, 2019, </em>the Company entered into a sales agreement with Jefferies LLC (“Jefferies”) to act as an agent in selling the Company’s ordinary shares in an at-the-market (“ATM”) offering program. As of <em style="font: inherit;"> December 31, 2022, </em>the Company received aggregate gross proceeds of $13,185 on 630,228 ordinary shares sold in respect thereof.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:20pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">On <em style="font: inherit;"> June 14, 2019 </em>and <em style="font: inherit;"> July 3, 2019, </em>certain investors led by Shenzhen Efung <em style="font: inherit;">9th</em> Venture Investment Center (Limited Partnership) (“Efung Capital”) entered into investment agreements with Dalian Wanchunbulin Pharmaceuticals Ltd. (“Wanchunbulin”), a subsidiary of the Company, to invest $14,537 (<span style="-sec-ix-hidden:c96612465">RMB100,000</span>) for a total of 4.76% equity interest of Wanchunbulin. As of <em style="font: inherit;"> December 31, 2021, </em>the Company received aggregate gross proceeds of $10,083 (<span style="-sec-ix-hidden:c96612468">RMB70,000</span>) from this equity financing.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 20pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">In <em style="font: inherit;"> July 2019, </em>the Company completed a public offering of the issuance of 2,058,825 ordinary shares of the Company at $17.00 per share for gross proceeds of $35,000.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 20pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">In <em style="font: inherit;"> October </em>and <em style="font: inherit;"> November 2019, </em>the Company completed a public offering of the issuance of 1,908,996 ordinary shares of the Company at $13.50 per share for gross proceeds of $25,771.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">In <em style="font: inherit;"> June 2020, </em>the Company completed a public offering of the issuance of 2,219,500 ordinary shares of the Company at $13.00 per share for gross proceeds of $28,854.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">On <em style="font: inherit;"> June 18, 2020, </em>the Company entered into a share subscription agreement for the sale of an aggregate of 384,615 ordinary shares at $13.00 per share in a private placement transaction. Gross proceeds of $5,000 was received in <em style="font: inherit;"> July 2020.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">In <em style="font: inherit;"> November 2020, </em>the Company completed a public offering of the issuance of 8,625,000 ordinary shares of the Company at $10.00 per share for gross proceeds of $86,250.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">On <em style="font: inherit;"> November 25, 2020, </em>SEED Therapeutics US, Inc. (“SEED US”) was incorporated in the United States (“U.S.”) as a wholly owned subsidiary of SEED Therapeutics Inc. (“SEED”).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">On <em style="font: inherit;"> March 22, 2022, </em>Wanchun Hongji (Dalian) Pharmaceuticals Ltd. (“Wanchun Hongji”) was incorporated in the People’s Republic of China (“PRC”) as a wholly owned subsidiary of SEED.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">As of <em style="font: inherit;"> December 31, 2022, </em>the subsidiaries of the Company are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font-family: Times New Roman; font-size: 10pt; width: 100%; margin-left: auto; margin-right: auto;"><tbody><tr><td style="vertical-align: bottom; width: 17%; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Name of company</b></p> </td><td style="vertical-align: bottom; width: 7.9%; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Place of incorporation</b></p> </td><td style="vertical-align: bottom; width: 5.2%; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date of incorporation</b></p> </td><td style="vertical-align: bottom; width: 6%; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Percentage of ownership </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>by the Company</b></p> </td><td style="vertical-align: bottom; width: 8.9%; border-bottom: 1px solid black;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Principal activities</b></p> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align:bottom;width:17%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">BeyondSpring Pharmaceuticals Inc. (“BeyondSpring US”)</p> </td><td style="vertical-align:bottom;width:7.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Delaware, U.S.</em></p> </td><td style="vertical-align:bottom;width:5.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">June 18, 2013</em></p> </td><td style="vertical-align:bottom;width:6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">100%</p> </td><td style="vertical-align:bottom;width:8.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Clinical trial activities</em></p> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="vertical-align:bottom;width:17%;"> </td><td style="vertical-align:bottom;width:7.9%;"> </td><td style="vertical-align:bottom;width:5.2%;"> </td><td style="vertical-align:bottom;width:6%;"> </td><td style="vertical-align:bottom;width:8.9%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align:bottom;width:17%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">BeyondSpring Ltd.</p> </td><td style="vertical-align:bottom;width:7.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">The British Virgin Islands (“BVI”)</em></p> </td><td style="vertical-align:bottom;width:5.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">December 3, 2014</em></p> </td><td style="vertical-align:bottom;width:6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">100%</p> </td><td style="vertical-align:bottom;width:8.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Holding company</em></p> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="vertical-align:bottom;width:17%;"> </td><td style="vertical-align:bottom;width:7.9%;"> </td><td style="vertical-align:bottom;width:5.2%;"> </td><td style="vertical-align:bottom;width:6%;"> </td><td style="vertical-align:bottom;width:8.9%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align:bottom;width:17%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">BeyondSpring (HK) Limited (“BeyondSpring HK”)</p> </td><td style="vertical-align:bottom;width:7.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Hong Kong</em></p> </td><td style="vertical-align:bottom;width:5.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">January 13, 2015</em></p> </td><td style="vertical-align:bottom;width:6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">100%</p> </td><td style="vertical-align:bottom;width:8.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Holding company</em></p> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="vertical-align:bottom;width:17%;"> </td><td style="vertical-align:bottom;width:7.9%;"> </td><td style="vertical-align:bottom;width:5.2%;"> </td><td style="vertical-align:bottom;width:6%;"> </td><td style="vertical-align:bottom;width:8.9%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align:bottom;width:17%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Wanchun Biotechnology Limited (“BVI Biotech”)</p> </td><td style="vertical-align:bottom;width:7.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">BVI</em></p> </td><td style="vertical-align:bottom;width:5.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">April 1, 2015</em></p> </td><td style="vertical-align:bottom;width:6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">100%</p> </td><td style="vertical-align:bottom;width:8.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Holding company</em></p> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="vertical-align:bottom;width:17%;"> </td><td style="vertical-align:bottom;width:7.9%;"> </td><td style="vertical-align:bottom;width:5.2%;"> </td><td style="vertical-align:bottom;width:6%;"> </td><td style="vertical-align:bottom;width:8.9%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align:bottom;width:17%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Wanchun Biotechnology (Dalian) Ltd. (“Wanchun Dalian”)</p> </td><td style="vertical-align:bottom;width:7.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">PRC</em></p> </td><td style="vertical-align:bottom;width:5.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">April 23, 2015</em></p> </td><td style="vertical-align:bottom;width:6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">100%</p> </td><td style="vertical-align:bottom;width:8.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Holding company</em></p> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="vertical-align:bottom;width:17%;"> </td><td style="vertical-align:bottom;width:7.9%;"> </td><td style="vertical-align:bottom;width:5.2%;"> </td><td style="vertical-align:bottom;width:6%;"> </td><td style="vertical-align:bottom;width:8.9%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align:bottom;width:17%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dalian Wanchunbulin Pharmaceuticals Ltd. (“Wanchunbulin”)</p> </td><td style="vertical-align:bottom;width:7.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">PRC</em></p> </td><td style="vertical-align:bottom;width:5.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">May 6, 2015</em></p> </td><td style="vertical-align:bottom;width:6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">57.97%</p> </td><td style="vertical-align:bottom;width:8.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Clinical trial activities</em></p> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="vertical-align:bottom;width:17%;"> </td><td style="vertical-align:bottom;width:7.9%;"> </td><td style="vertical-align:bottom;width:5.2%;"> </td><td style="vertical-align:bottom;width:6%;"> </td><td style="vertical-align:bottom;width:8.9%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align:bottom;width:17%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">BeyondSpring Pharmaceuticals Australia PTY Ltd.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(“BeyondSpring Australia”)</p> </td><td style="vertical-align:bottom;width:7.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Australia</em></p> </td><td style="vertical-align:bottom;width:5.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">March 3, 2016</em></p> </td><td style="vertical-align:bottom;width:6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">100%</p> </td><td style="vertical-align:bottom;width:8.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Clinical trial activities</em></p> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="vertical-align:bottom;width:17%;"> </td><td style="vertical-align:bottom;width:7.9%;"> </td><td style="vertical-align:bottom;width:5.2%;"> </td><td style="vertical-align:bottom;width:6%;"> </td><td style="vertical-align:bottom;width:8.9%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align:bottom;width:17%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Beijing Wanchun Pharmaceutical Technology Ltd.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(“Beijing Wanchun”)</p> </td><td style="vertical-align:bottom;width:7.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">PRC</em></p> </td><td style="vertical-align:bottom;width:5.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">May 21, 2018</em></p> </td><td style="vertical-align:bottom;width:6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">57.97%</p> </td><td style="vertical-align:bottom;width:8.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Holding company</em></p> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="vertical-align:bottom;width:17%;"> </td><td style="vertical-align:bottom;width:7.9%;"> </td><td style="vertical-align:bottom;width:5.2%;"> </td><td style="vertical-align:bottom;width:6%;"> </td><td style="vertical-align:bottom;width:8.9%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align:bottom;width:17%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">SEED Therapeutics Inc. (“SEED”)</p> </td><td style="vertical-align:bottom;width:7.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">BVI</em></p> </td><td style="vertical-align:bottom;width:5.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">June 25, 2019</em></p> </td><td style="vertical-align:bottom;width:6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">55.05%</p> </td><td style="vertical-align:bottom;width:8.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Pre-clinical development activities</em></p> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="vertical-align:bottom;width:17%;"> </td><td style="vertical-align:bottom;width:7.9%;"> </td><td style="vertical-align:bottom;width:5.2%;"> </td><td style="vertical-align:bottom;width:6%;"> </td><td style="vertical-align:bottom;width:8.9%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align:bottom;width:17%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">SEED Technology Limited (“SEED Technology”)</p> </td><td style="vertical-align:bottom;width:7.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">BVI</em></p> </td><td style="vertical-align:bottom;width:5.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">December 9, 2019</em></p> </td><td style="vertical-align:bottom;width:6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">57.97%</p> </td><td style="vertical-align:bottom;width:8.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Holding company</em></p> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="vertical-align:bottom;width:17%;"> </td><td style="vertical-align:bottom;width:7.9%;"> </td><td style="vertical-align:bottom;width:5.2%;"> </td><td style="vertical-align:bottom;width:6%;"> </td><td style="vertical-align:bottom;width:8.9%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align:bottom;width:17%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">SEED Therapeutics US, Inc. (“SEED US”)</p> </td><td style="vertical-align:bottom;width:7.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Delaware, U.S.</em></p> </td><td style="vertical-align:bottom;width:5.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">November 25, 2020</em></p> </td><td style="vertical-align:bottom;width:6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">55.05%</p> </td><td style="vertical-align:bottom;width:8.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Pre-clinical development activities</em></p> </td></tr> <tr style="background-color: rgb(255, 255, 255);"><td style="vertical-align:bottom;width:17%;"> </td><td style="vertical-align:bottom;width:7.9%;"> </td><td style="vertical-align:bottom;width:5.2%;"> </td><td style="vertical-align:bottom;width:6%;"> </td><td style="vertical-align:bottom;width:8.9%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align:bottom;width:17%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Wanchun Hongji (Dalian) Pharmaceuticals Ltd. (“Wanchun Hongji”)</p> </td><td style="vertical-align:bottom;width:7.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">PRC</em></p> </td><td style="vertical-align:bottom;width:5.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">March 22, 2022</em></p> </td><td style="vertical-align:bottom;width:6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">55.05%</p> </td><td style="vertical-align:bottom;width:8.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Pre-clinical development activities</em></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b/></p>
CY2022	us-gaap	Profit Loss ProfitLoss	-36280000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-375276000	usd
CY2022Q4	bysi	Net Current Assets NetCurrentAssets	31171000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	37268000	usd
CY2022	bysi	Effective Income Tax Rate Reconciliation Current And Deferred Tax Rate Differences EffectiveIncomeTaxRateReconciliationCurrentAndDeferredTaxRateDifferences	-672000	usd
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	0	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	0	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b><i>Use of estimates</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the period. Areas where management uses subjective judgment include, but are <em style="font: inherit;">not</em> limited to, share-based compensation, clinical trial accruals, valuation allowance for deferred tax assets, estimating uncertain tax positions, measurement of right-of-use assets and lease liabilities, fair value of financial instruments, estimating the allowance for credit losses, impairment of long-lived assets and estimating of useful life for property and equipment. Management bases the estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from these estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"/>
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	389000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2020	bysi	Effective Income Tax Rate Reconciliation Nondeductible Expense Interest Expense Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount	-0	usd
CY2021	bysi	Effective Income Tax Rate Reconciliation Nondeductible Expense Interest Expense Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount	-0	usd
CY2022	bysi	Effective Income Tax Rate Reconciliation Nondeductible Expense Interest Expense Amount EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount	315000	usd
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	8891000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	17170000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-63821000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-64638000	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b><i>Concentration of risks</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><span style="text-decoration: underline; ">Concentration of credit risk</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company’s cash and cash equivalents and short-term investments are held at financial institutions that management believes to be of high credit quality. As of <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2022,</em> the majority of the cash and cash equivalents were held by financial institutions located in U.S. and short-term investments were held by financial institutions located in U.S. and China.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">PRC state-owned banks, such as China Merchants Bank, Bank of China, are subject to a series of risk control regulatory standards, and PRC bank regulatory authorities are empowered to take over the operation and management when any of those banks faces a material credit crisis. The Company does <em style="font: inherit;">not</em> foresee substantial credit risk with respect to cash and cash equivalents and short-term investments held at the PRC state-owned banks. In <em style="font: inherit;"> May 2015, </em>a new Deposit Insurance System (“DIS”) managed by the People’s Bank of China (‘‘PBOC’’) was implemented by the Chinese government. Deposits in the licensed banks in mainland China are protected by DIS, up to a limit of <em style="font: inherit;">RMB500.</em> In the event of bankruptcy of <em style="font: inherit;">one</em> of the financial institutions in which the Company has deposits or investments, it <em style="font: inherit;"> may </em>be unlikely to claim its deposits or investments back in full. The Company selected reputable financial institutions with high rating rates to place its currencies. The Company regularly monitors the rating of the financial institutions to avoid any potential defaults. The Company has <em style="font: inherit;">not</em> experienced any losses on cash and cash equivalents and short-term investments to date. The Company does <em style="font: inherit;">not</em> believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><span style="text-decoration: underline; ">Business, customer, political, social and economic risks</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">The Company participates in a dynamic biopharmaceutical industry and believes that changes in any of the following areas could have a material adverse effect on the Company’s future financial position, results of operations, or cash flows: changes in the overall demand for services and products; competitive pressures due to existing competitors and new entrants; advances and new trends in new drugs and industry standards; changes in clinical research organizations and other key vendors; changes in certain strategic relationships or customer relationships; regulatory considerations; intellectual property considerations; and risks associated with the Company’s ability to attract and retain employees necessary to support its operations. The Company’s operations could be also adversely affected by significant political, economic and social uncertainties in the PRC and in relations between the PRC and United States.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><span style="text-decoration: underline; ">Business risk</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">The Company relies on <em style="font: inherit;">third</em> parties to support clinical development activities, trials and the manufacturing process for product candidates. If these <em style="font: inherit;">third</em> parties do <em style="font: inherit;">not</em> successfully carry out their contractual duties or meet expected deadlines, the Company <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be able to obtain regulatory approval for the Company’s drug candidates and the Company’s business could be substantially impacted. The Company’s main activities are in U.S. and PRC.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b/></p><p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b><i/></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><span style="text-decoration: underline; ">Currency convertibility risk</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">The Company incurs portions of expenses in currencies other than the U.S. dollars, in particular, the RMB. On <em style="font: inherit;"> January 1, 1994, </em>the PRC government abolished the dual rate system and introduced a single rate of exchange as quoted daily by the PBOC. However, the unification of the exchange rates does <em style="font: inherit;">not</em> imply that the RMB <em style="font: inherit;"> may </em>be readily convertible into U.S. dollars or other foreign currencies. All foreign exchange transactions continue to take place either through the PBOC or other banks authorized to buy and sell foreign currencies at the exchange rates quoted by the PBOC. Approvals of foreign currency payments by the PBOC or other institutions require submitting a payment application form together with suppliers’ invoices, shipping documents and signed contracts.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">Additionally, the value of the RMB is subject to changes in central government policies and international economic and political developments affecting supply and demand in the PRC foreign exchange trading system market.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><span style="text-decoration: underline; ">Foreign currency exchange rate risk</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">From <em style="font: inherit;"> July 21, 2005, </em>the RMB is permitted to fluctuate within a narrow and managed band against a basket of certain foreign currencies. The appreciation of RMB against the U.S. dollar was approximately 6.3% for the year ended <em style="font: inherit;"> December 31, 2020, </em>the appreciation of RMB against the U.S. dollar was approximately 2.3% for the year ended <em style="font: inherit;"> December 31, 2021, </em>and the depreciation of RMB against the U.S. dollar was approximately 8.2% for the year ended <em style="font: inherit;"> December 31, 2022. </em>It is difficult to predict how market forces or PRC or U.S. government policy <em style="font: inherit;"> may </em>impact the exchange rate between the RMB and the U.S. dollar in the future.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">To the extent that the Company needs to convert U.S. dollars into RMB for capital expenditures and working capital and other business purposes, appreciation of the RMB against the U.S. dollar would have an adverse effect on the RMB amount the Company would receive from the conversion. Conversely, if the Company decides to convert RMB into U.S. dollars for the purpose of making payments for dividends on ordinary shares, strategic acquisitions or investments or other business purposes, appreciation of the U.S. dollar against the RMB would have a negative effect on the U.S. dollar amount available to the Company. In addition, a significant depreciation of the RMB against the U.S. dollar <em style="font: inherit;"> may </em>significantly reduce the U.S. dollar equivalent of the Company’s earnings or losses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b/></p><table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: auto;"><p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b/></p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"/>
CY2020	bysi	Depreciation Of Rmb Against Us Dollar Percent DepreciationOfRMBAgainstUSDollarPercent	0.063	pure
CY2021	bysi	Depreciation Of Rmb Against Us Dollar Percent DepreciationOfRMBAgainstUSDollarPercent	0.023	pure
CY2022	bysi	Depreciation Of Rmb Against Us Dollar Percent DepreciationOfRMBAgainstUSDollarPercent	0.082	pure
CY2021Q4	bysi	Debt Securities Trading And Availableforsale Amortized Cost DebtSecuritiesTradingAndAvailableforsaleAmortizedCost	30594000	usd
CY2021Q4	bysi	Debt Securities Trading And Availableforsale Accumulated Gross Unrealized Gains Before Tax DebtSecuritiesTradingAndAvailableforsaleAccumulatedGrossUnrealizedGainsBeforeTax	149000	usd
CY2021Q4	bysi	Debt Securities Trading And Availableforsale Accumulated Gross Unrealized Losses Before Tax DebtSecuritiesTradingAndAvailableforsaleAccumulatedGrossUnrealizedLossesBeforeTax	-0	usd
CY2021Q4	us-gaap	Debt Securities Trading And Available For Sale DebtSecuritiesTradingAndAvailableForSale	30743000	usd
CY2022Q4	bysi	Debt Securities Trading And Availableforsale Amortized Cost DebtSecuritiesTradingAndAvailableforsaleAmortizedCost	2853000	usd
CY2022Q4	bysi	Debt Securities Trading And Availableforsale Accumulated Gross Unrealized Gains Before Tax DebtSecuritiesTradingAndAvailableforsaleAccumulatedGrossUnrealizedGainsBeforeTax	19000	usd
CY2022Q4	bysi	Debt Securities Trading And Availableforsale Accumulated Gross Unrealized Losses Before Tax DebtSecuritiesTradingAndAvailableforsaleAccumulatedGrossUnrealizedLossesBeforeTax	-0	usd
CY2022Q4	us-gaap	Debt Securities Trading And Available For Sale DebtSecuritiesTradingAndAvailableForSale	2872000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-36117000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1741000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2419000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	319000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	551000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1422000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1868000	usd
CY2020	us-gaap	Depreciation Depreciation	77000	usd
CY2021	us-gaap	Depreciation Depreciation	61000	usd
CY2022	us-gaap	Depreciation Depreciation	232000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3570000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	7607000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3570000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	163000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.85
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3570000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	163000	usd
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3570000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	163000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-63821000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-64638000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-36117000	usd
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-13403000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-13574000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-7585000	usd
CY2020	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	4653000	usd
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	3796000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	2253000	usd
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	688000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	788000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	-812000	usd
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	641000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1096000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1437000	usd
CY2020	us-gaap	Income Tax Reconciliation Tax Exempt Income IncomeTaxReconciliationTaxExemptIncome	120000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Exempt Income IncomeTaxReconciliationTaxExemptIncome	21000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Exempt Income IncomeTaxReconciliationTaxExemptIncome	0	usd
CY2020	bysi	Effective Income Tax Rate Reconciliation Tax Preference Amount EffectiveIncomeTaxRateReconciliationTaxPreferenceAmount	0	usd
CY2021	bysi	Effective Income Tax Rate Reconciliation Tax Preference Amount EffectiveIncomeTaxRateReconciliationTaxPreferenceAmount	3755000	usd
CY2022	bysi	Effective Income Tax Rate Reconciliation Tax Preference Amount EffectiveIncomeTaxRateReconciliationTaxPreferenceAmount	-667000	usd
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-68000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	262000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	216000	usd
CY2020	bysi	Effective Income Tax Rate Reconciliation Current And Deferred Tax Rate Differences EffectiveIncomeTaxRateReconciliationCurrentAndDeferredTaxRateDifferences	-0	usd
CY2021	bysi	Effective Income Tax Rate Reconciliation Current And Deferred Tax Rate Differences EffectiveIncomeTaxRateReconciliationCurrentAndDeferredTaxRateDifferences	-0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	24211000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	26571000	usd
CY2021Q4	bysi	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Tax Deduction Of Research And Development DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsTaxDeductionOfResearchAndDevelopment	6757000	usd
CY2022Q4	bysi	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Tax Deduction Of Research And Development DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsTaxDeductionOfResearchAndDevelopment	6857000	usd
CY2021Q4	bysi	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	0	usd
CY2022Q4	bysi	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	3819000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1482000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1591000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	9510000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	8630000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	4063000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	5295000	usd
CY2021Q4	bysi	Deferred Tax Assets Lease Liability Obligation DeferredTaxAssetsLeaseLiabilityObligation	422000	usd
CY2022Q4	bysi	Deferred Tax Assets Lease Liability Obligation DeferredTaxAssetsLeaseLiabilityObligation	1043000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	11000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	21000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	46456000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	53827000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	37000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	41000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	254000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	346000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	420000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1153000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	711000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1540000	usd
CY2021Q4	bysi	Deferred Tax Assets Liabilities Gross Net DeferredTaxAssetsLiabilitiesGrossNet	45745000	usd
CY2022Q4	bysi	Deferred Tax Assets Liabilities Gross Net DeferredTaxAssetsLiabilitiesGrossNet	52287000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	45745000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	52287000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1065000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3634000	usd
CY2021Q4	bysi	Deferred Tax Assets Unrecognized Tax Benefit DeferredTaxAssetsUnrecognizedTaxBenefit	427000	usd
CY2022Q4	bysi	Deferred Tax Assets Unrecognized Tax Benefit DeferredTaxAssetsUnrecognizedTaxBenefit	1391000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	638000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	2243000	usd
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.64
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	956000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	730000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1065000	usd
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	283000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	3099000	usd
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	226000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	-0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	608000	usd
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	52000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	78000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	730000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1065000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3634000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	315000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	203000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	518000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-60973000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-64179000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-33279000	usd
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29984284
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39023643
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39093246
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.03
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	8.54
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8194000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3152000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1584000	usd
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	130000	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	303000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	236000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	959000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	436000	usd
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	878000	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	725000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	1107000	usd
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	20000	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	116000	usd
CY2022Q4	us-gaap	Short Term Lease Commitment Amount ShortTermLeaseCommitmentAmount	54000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1165000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	785000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	804000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	824000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	521000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1563000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5662000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	701000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4961000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	675000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	1471000	usd
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y11M23D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y7M9D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.055	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.036	pure
CY2021Q4	bysi	Prepayment Of Property And Equipment Noncurrent PrepaymentOfPropertyAndEquipmentNoncurrent	1544000	usd
CY2022Q4	bysi	Prepayment Of Property And Equipment Noncurrent PrepaymentOfPropertyAndEquipmentNoncurrent	0	usd
CY2021Q4	bysi	Deductible Input Value Added Tax Noncurrent DeductibleInputValueAddedTaxNoncurrent	1304000	usd
CY2022Q4	bysi	Deductible Input Value Added Tax Noncurrent DeductibleInputValueAddedTaxNoncurrent	8000	usd
CY2021Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	271000	usd
CY2022Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	339000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3119000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	347000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1803000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1330000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	6000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	6000	usd
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	3570000	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	16000	usd
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	426000	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	16000	usd
CY2021Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	360000	usd
CY2022Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	116000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	6165000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1484000	usd
CY2021Q4	bysi	Employee Related Liabilities Noncurrent EmployeeRelatedLiabilitiesNoncurrent	87000	usd
CY2022Q4	bysi	Employee Related Liabilities Noncurrent EmployeeRelatedLiabilitiesNoncurrent	85000	usd
CY2021Q4	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	622000	usd
CY2022Q4	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	3240000	usd
CY2021Q4	bysi	Taxes Payable Noncurrent TaxesPayableNoncurrent	0	usd
CY2022Q4	bysi	Taxes Payable Noncurrent TaxesPayableNoncurrent	336000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	709000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3661000	usd
CY2019Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	0	usd
CY2020	bysi	Redeemable Noncontrolling Interest Issuance RedeemableNoncontrollingInterestIssuance	5196000	usd
CY2020Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	5196000	usd
CY2021	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	258000	usd
CY2021Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	5454000	usd
CY2022	bysi	Redeemable Noncontrolling Interest Issuance RedeemableNoncontrollingInterestIssuance	3763000	usd
CY2022	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	1857000	usd
CY2022Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	11074000	usd
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	140000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-437000	usd
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-297000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-226000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-523000	usd
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	180000	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	41793000	usd
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	22598000	usd
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-64211000	usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1351000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	36888000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	30703000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-66240000	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1351000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25582000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13008000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-37239000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1122000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-36117000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	163000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-36280000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-3001000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-33279000	usd
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	180000	usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1351000	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1351000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1422000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1868000	usd

Files In Submission

Name	View Source	Status
0001171843-23-002373-index-headers.html	Edgar Link	pending
0001171843-23-002373-index.html	Edgar Link	pending
0001171843-23-002373.txt	Edgar Link	pending
0001171843-23-002373-xbrl.zip	Edgar Link	pending
bysi-20221231.xsd	Edgar Link	pending
bysi20221230_20f.htm	Edgar Link	pending
ex_500853.htm	Edgar Link	pending
ex_500854.htm	Edgar Link	pending
ex_500856.htm	Edgar Link	pending
ex_500857.htm	Edgar Link	pending
bysi-20221231_cal.xml	Edgar Link	unprocessable
bysi-20221231_pre.xml	Edgar Link	unprocessable
bysi-20221231_def.xml	Edgar Link	unprocessable
bysi-20221231_lab.xml	Edgar Link	unprocessable
bysi20221230_20f_htm.xml	Edgar Link	completed
ex_500858.htm	Edgar Link	pending
ex_500859.htm	Edgar Link	pending
ex_500860.htm	Edgar Link	pending
ex_500861.htm	Edgar Link	pending
ex_500862.htm	Edgar Link	pending
ex_500895.htm	Edgar Link	pending
ex_500908.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
logo.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
p118organizationalstructurec.jpg	Edgar Link	pending
p83ourpipelinecopy.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BYSI
BeyondSpring Inc. Stock $bysi

2022 Q4 Form 20-F Financial Statement

#000117184323002373 Filed on April 18, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BYSI BeyondSpring Inc. Stock $bysi

2022 Q4 Form 20-F Financial Statement

#000117184323002373 Filed on April 18, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BYSI
BeyondSpring Inc. Stock $bysi